These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy. Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N. Clin Exp Rheumatol; 2007; 25(2):206-10. PubMed ID: 17543143 [Abstract] [Full Text] [Related]
6. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate. de la Piedra C, Rapado A, Díaz Diego EM, Díaz Martín MA, Aguirre C, López Gavilanes E, Díaz Curiel M. Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976 [Abstract] [Full Text] [Related]
8. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. Alvarez L, Guañabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, Martinez de Osaba MJ, Muñoz-Gomez J, Rivera-Fillat F, Ballesta AM. J Bone Miner Res; 1995 Mar; 10(3):458-65. PubMed ID: 7785468 [Abstract] [Full Text] [Related]
9. Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. Alvarez L, RicOs C, Peris P, GuaNabens N, Monegal A, Pons F, Ballesta AM. Bone; 2000 Jun; 26(6):571-6. PubMed ID: 10831927 [Abstract] [Full Text] [Related]
10. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. Alexandersen P, Peris P, Guañabens N, Byrjalsen I, Alvarez L, Solberg H, Cloos PA. J Bone Miner Res; 2005 Apr; 20(4):588-95. PubMed ID: 15765177 [Abstract] [Full Text] [Related]
13. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Alvarez L, Peris P, Guañabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Muñoz-Gomez J, Ballesta AM. Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438 [Abstract] [Full Text] [Related]
15. Clinical efficacy of oral risedronate therapy in Japanese patients with Paget's disease of bone. Ohara M, Imanishi Y, Nagata Y, Ishii A, Kobayashi I, Mori K, Ito M, Miki T, Nishizawa Y, Inaba M. J Bone Miner Metab; 2015 Sep; 33(5):584-90. PubMed ID: 25319558 [Abstract] [Full Text] [Related]
17. Biochemical assessment of Paget's disease of bone. Shankar S, Hosking DJ. J Bone Miner Res; 2006 Dec; 21 Suppl 2():P22-7. PubMed ID: 17229003 [Abstract] [Full Text] [Related]
18. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Ebert W, Muley T, Herb KP, Schmidt-Gayk H. Anticancer Res; 2004 Dec; 24(5B):3193-201. PubMed ID: 15510610 [Abstract] [Full Text] [Related]
19. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Peris P, Alvarez L, Monegal A, Guañabens N, Durán M, Pons F, Martínez de Osaba MJ, Echevarría M, Ballesta AM, Muñoz-Gómez J. Bone; 1999 Sep; 25(3):349-53. PubMed ID: 10495139 [Abstract] [Full Text] [Related]